» Articles » PMID: 10585479

Quinolones Inhibit DNA Religation Mediated by Staphylococcus Aureus Topoisomerase IV. Changes in Drug Mechanism Across Evolutionary Boundaries

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1999 Dec 10
PMID 10585479
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.

Citing Articles

Interactions between Zoliflodacin and Gyrase and Topoisomerase IV: Enzymological Basis for Cellular Targeting.

Collins J, Basarab G, Chibale K, Osheroff N ACS Infect Dis. 2024; 10(8):3071-3082.

PMID: 39082980 PMC: 11320581. DOI: 10.1021/acsinfecdis.4c00438.


Immunomodulatory Effects of Fluoroquinolones in Community-Acquired Pneumonia-Associated Acute Respiratory Distress Syndrome.

Yudhawati R, Wicaksono N Biomedicines. 2024; 12(4).

PMID: 38672119 PMC: 11048665. DOI: 10.3390/biomedicines12040761.


Target-Mediated Fluoroquinolone Resistance in : Actions of Ciprofloxacin against Gyrase and Topoisomerase IV.

Collins J, Oviatt A, Chan P, Osheroff N ACS Infect Dis. 2024; 10(4):1351-1360.

PMID: 38606464 PMC: 11015056. DOI: 10.1021/acsinfecdis.4c00041.


Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.

Collins J, Osheroff N ACS Infect Dis. 2024; 10(4):1097-1115.

PMID: 38564341 PMC: 11019561. DOI: 10.1021/acsinfecdis.4c00128.


Actions of a Novel Bacterial Topoisomerase Inhibitor against Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks.

Dauda S, Collins J, Byl J, Lu Y, Yalowich J, Mitton-Fry M Int J Mol Sci. 2023; 24(15).

PMID: 37569485 PMC: 10419083. DOI: 10.3390/ijms241512107.